Within the tumor microenvironment (TME), regulatory T cells (Tregs) play a key role in suppressing anticancer immune responses; therefore, various strategies targeting Tregs are becoming important for ...

After decades of investment, antibody–drug conjugates (ADCs) are finally demonstrating their potential, marked by a growing number of clinical approvals, applications in earlier lines of treatment and ...

Over the past two decades, numerous complex cancer therapies called antibody drug conjugates (ADCs) have been tested in clinical trials and approved for use in patients. Investigators recently ...

Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...